The Scorpion Therapeutics spinoff sold rights for two EGFR inhibitors to Pierre Fabre Laboratories and is hoping to become a clinical-stage firm by 2026.

In JAMA, the FDA's Makary and Prasad said they will focus on modernizing review processes and lowering drug costs but don't outright mention precision medicine.

The US Food and Drug Administration has granted Nuevocor permission to begin a first-in-human trial of NVC-001, a gene therapy it is developing for LMNA-related dilated cardiomyopathy (LMNA-DCM), the ...